<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974674</url>
  </required_header>
  <id_info>
    <org_study_id>P030415</org_study_id>
    <nct_id>NCT01974674</nct_id>
  </id_info>
  <brief_title>Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes</brief_title>
  <acronym>GRIIF</acronym>
  <official_title>Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a multicentre, sequential, phase II clinical trial, aiming at evaluating the allogeneic&#xD;
      islet transplantation for the treatment of type 1 diabetes.&#xD;
&#xD;
      19 patients with type 1 diabetes will be included and ideally distributed evenly: patients&#xD;
      with unstable diabetes without renal insufficiency (AI group for &quot;islet alone&quot; by the&#xD;
      international customary determination) and patients with a functioning kidney transplant (IAK&#xD;
      group for &quot;islet after kidney&quot;). The main endpoint will be defined by the restoration of&#xD;
      normal glycemic control without insulin at 6 months after graft.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>restoration of normal glycemic control without insulin</measure>
    <time_frame>6 months after graft</time_frame>
    <description>the restoration of normal glycemic control without insulin therapy will be evaluated by measuring&#xD;
- A fasting glucose (&gt; 8 hours) less than 1.25 g/L and a 2 hours glucose after oral intake of 75g of glucose, less than 2 g/L in a patient without insulin for at least 15 consecutive days during the the first 6 months from day 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restoration of normal glycemic control without insulin for a year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obtaining an improvement in glycemic control</measure>
    <time_frame>within 2 years after inclusion</time_frame>
    <description>HbA1c &lt;6.5%, with lower insulin doses by 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obtaining a remission of diabetes</measure>
    <time_frame>within 2 years after inclusion</time_frame>
    <description>The remission of diabetes is defined by the normality of blood glucose or insulin without lHbA1c.&#xD;
The normality of blood glucose is defined below 1.20 g/L and postprandial fasting glycemia less than 1.60 g/L in the book self-monitoring (including 6/7 blood glucoses during the previous 3 days evaluation visit).&#xD;
Normal HbA1c is defined as less than 6.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved metabolic profile determined by the OGTT and hyperglycemic clamp</measure>
    <time_frame>within 2 years after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased glycemic variability</measure>
    <time_frame>within 2 years after inclusion</time_frame>
    <description>defined on blood glucose and / or glucose holter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of oxidative stress assessed by the urinary excretion of 24 hours of 8-iso-PGF2 rates.</measure>
    <time_frame>within 2 years after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in the frequency, severity or poor perception of hypoglycaemia defined Hypo score</measure>
    <time_frame>within the 2 years after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>within 2 years after inclusion</time_frame>
    <description>defined by questionnaires DQOL and SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>term graft survival</measure>
    <time_frame>within 2 years of inclusion</time_frame>
    <description>defined by the rate of C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beta-cell function</measure>
    <time_frame>2 years</time_frame>
    <description>based on beta-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>potential of each infusion of islets</measure>
    <time_frame>within 2 years after inclusion</time_frame>
    <description>number of IEQ/kg of recipient required to reduce the daily insulin dose of 1 unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>degenerative complications of diabetes</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Patients With Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Allogeneic transplantation of intrahepatic islet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic transplantation of intrahepatic islet number required for insulin independence of obtaining, with a threshold dose of 9,000 IEQ/kg body weight of the recipient and a maximum sequence number of 3 infusions. The patient will receive after transplantation immunosuppressive therapy with Thymoglobulin for induction, Prograf and Cellcept, both of which are given throughout the duration of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic transplantation of intrahepatic islet</intervention_name>
    <arm_group_label>Allogeneic transplantation of intrahepatic islet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 1 diabetes&#xD;
&#xD;
          -  18 &lt;Age &lt;55 years&#xD;
&#xD;
          -  Plasma C-peptide &lt;0.2 ng/ml basal and stimulated glucagon&#xD;
&#xD;
          -  Evolution of diabetes for more than 5 years&#xD;
&#xD;
          -  Regular patient follow-up (&gt; or equal to 2 visits per year from the same&#xD;
             diabetologist)&#xD;
&#xD;
          -  Patient who received the information and have given their consent in writing&#xD;
&#xD;
          -  Absence of HIV, hepatitis B and hepatitis C, HTLV-1-2&#xD;
&#xD;
          -  ABO compatibility with the donor&#xD;
&#xD;
          -  Cross match negative&#xD;
&#xD;
          -  Anti-HLA antibodies (class I and / or class II) detected by lymphocytotoxicity &lt;20%&#xD;
&#xD;
          -  PCR negative for the BK virus in the blood (so as not to amplify the BK virus&#xD;
             replication with the ATG).&#xD;
&#xD;
          -  Accepting patients effective contraception during the study period&#xD;
&#xD;
        For patients in group IA&#xD;
&#xD;
          -  Glomerular filtration rate estimated by the MDRD&gt; 50 ml/min/1.73m2&#xD;
&#xD;
          -  No perception of hypoglycaemia (less than 0.54 mg/dl glucose) at least one value&#xD;
             documented in the two years preceding and/or&#xD;
&#xD;
          -  Occurrence of at least one severe hypoglycemic episode (with a third required) and&#xD;
             unexplained in the two years before and/or at least two episodes of ketoacidosis per&#xD;
             year&#xD;
&#xD;
          -  Average HbA1c&gt; 8.5% over two years, despite intensified treatment (basal pattern,&#xD;
             bolus)&#xD;
&#xD;
             • For patients in the IAK&#xD;
&#xD;
          -  functional renal graft for at least 1 year&#xD;
&#xD;
          -  glomerular filtration rate&gt; 50 ml/min/1.73 m2&#xD;
&#xD;
          -  proteinuria &lt;0.5 g/day&#xD;
&#xD;
          -  Absence of acute rejection in renal previous 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 28&#xD;
&#xD;
          -  Need insulin &gt; 1 U/kg per day&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Intention of childbearing for the two sexes&#xD;
&#xD;
          -  Psychiatric Disorders&#xD;
&#xD;
          -  Inability to communicate or cooperate with the investigator&#xD;
&#xD;
          -  Lack of therapeutic compliance, including HbA1C &gt; 12%&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  Progressive heart disease myocardial infarction within 6 months prior to inclusion,&#xD;
             unbalanced CHD)&#xD;
&#xD;
          -  Proliferative retinopathy unstabilized&#xD;
&#xD;
          -  History of cancer, whatever the date, except for basal or squamous cell skin cancers&#xD;
             over 1 year.&#xD;
&#xD;
          -  Systemic infection&#xD;
&#xD;
          -  Chronic high risk of requiring corticosteroids&#xD;
&#xD;
          -  Need for long-term corticosteroid, outside that specified in renal transplantation,&#xD;
             the patients will be weaned before transplantation&#xD;
&#xD;
          -  Anticoagulant vitamin K or antiplatelet treatments&#xD;
&#xD;
          -  Disorders of hemostasis TP &lt;60 % TCA &gt; 1.5 times the control&#xD;
&#xD;
          -  Anti-HLA antibodies ( class I and/or class II ) detected by lymphocytotoxicity &gt; 20%&#xD;
&#xD;
          -  Platelets &lt; 100 giga/L and/or neutrophils &lt;1.5 giga/L&#xD;
&#xD;
          -  Chronic intoxication by alcohol, tobacco, or other substance (abstinence &gt; 6 months&#xD;
             required)&#xD;
&#xD;
          -  Active infection by hepatitis B, hepatitis C and HIV, HTLV-1-HTLV2&#xD;
&#xD;
          -  Ascites&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre CATTAN, MD PhD</last_name>
    <phone>33 1 42494786</phone>
    <email>pierre.cattan@sls.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Louis hospital</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre CATTAN, MD PhD</last_name>
      <phone>33 1 42494786</phone>
      <email>pierre.cattan@sls.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

